Kaposi's sarcoma and its associated herpesvirus

Enrique A. Mesri,Ethel Cesarman,Chris Boshoff
DOI: https://doi.org/10.1038/nrc2888
IF: 78.5
2010-09-24
Nature Reviews Cancer
Abstract:Key PointsKaposi's sarcoma herpesvirus (KSHV; also known as human herpesvirus 8 (HHV8)) is the causative agent of Kaposi's sarcoma (KS) and certain lymphoproliferations, and its seroepidemiology correlates with the global incidence of KS.KS is the most common neoplasm in untreated HIV-infected individuals, and also occurs in other states of immunosuppression, including after an organ transplant.KSHV is transmitted through saliva and replicates in oropharyngeal cells.Unlike most cancer cells, KS tumour cells are not fully transformed, do not show autonomous growth, and remain dependent on exogenous cytokines for in vitro growth.KS starts as a proliferation of endothelial-type cells, with an early onset inflammatory and abnormal leaky blood vessel expansion.KSHV is present in the vast majority of KS tumour cells (that is, spindle cells), expressing the latent viral proteins, including viral cyclin, viral FLICE inhibitory protein, latency-associated nuclear antigen (LANA) and a group of viral microRNAs.A proportion of cells in KS lesions seem to undergo lytic replication, expressing lytic viral proteins including K1, viral interleukin-6, viral BCL-2, viral G protein-coupled receptor, K15 and viral chemokines.KSHV latent genes drive cell proliferation and prevent apoptosis; whereas KSHV lytic genes could further contribute to KS tumorigenesis by triggering host signalling cascades that lead to cytokine and growth factor secretion.Biological insights into KSHV oncogenesis are leading to promising rational therapeutic approaches.
oncology
What problem does this paper attempt to address?